George Eldridge joined Targanta Therapeutics in September 2006. Previously he served as Senior Vice President, Chief Financial Officer at Therion Biologics, a privately held pharmaceutical company which is developing therapeutic vaccines for cancer. Prior to joining Therion in 2002, George served as Vice President of Finance and Chief Financial Officer of Curis.

While with Curis and, prior to merging, Ontogeny, Inc., George was responsible for securing corporate investments and raising over $100 million in three institutional equity offerings. He also led the successful integration of all departments in the three-way merger among Creative BioMolecules, Ontogeny and Reprogenesis that created Curis in August of 2000. Prior to joining Curis, George was Chief Financial Officer for Boston Life Sciences, Inc., and was an investment banker at Kidder Peabody & Co., Inc. George earned a M.B.A. from the University of Chicago, and a B.A. in government and economics from Dartmouth College.